ArcticZymes Technologies — Investor Presentation 2025

Jun 4, 2025

The Enzyme Experts

Nordic Small & Mid Cap Seminar 2025 Handelsbanken

June 4, 2025 CEO Michael Akoh CFO Børge Sørvoll

Overview Overview

A Norwegian biotech with growth potential Positioned for Profitable Growth in Biotech

A provider of novel enzymes for advanced therapies and molecular Targeting segments with considerable growth potential Worldclass Products

World class R&D team • Provide novel enzymes for advanced therapies and molecular diagnostics

diagnostics

No debt – 250 NMOK in Cash reserve

2

and strong manufacturing capabilities complying to both ISO13485 and GMP Margins above 90% across all products • Strong reputation in Molecular Tools and Bioprocessing segments

Listed on the Norwegian Stock Exchange

Customers are life science tools companies, CDMO, Pharma and World class products and reputation in Molecular Tools and Bioprocessing Segment & Customers

segments

US and Europe

• Targeting segments with high growth potential
• Recuring revenue streams – sticky business Sales of 119 MNOK (2023), positive cash flow and results • Customers are life science tools, CDMO, Pharma and Biotech companies

biotech

55 employees, Headquartered in Tromsø

International management and Board

Talent & Culture

• Management team committed to creating a culture where exceptional innovation thrives
• World class R&D team
• Strong manufacturing capabilities complying to ISO13485 and GMP
• Direct sales force in the • 53 employees, HQ in Tromsø
  • Direct sales in US & Europe more than 90% of business

Strong Financials

• Margins > 90% all products
• Recurring revenue streams sticky business
• Sales of 108 MNOK (2024)
• No debt 240 MNOK in Cash reserve
• Listed on the Norwegian Stock Exchange

B2B Value chain

Biomanufacturing and Molecular Tools customers

Biomanufacturing

Molecular Tools

Growing Markets

Targeting high-growth Biomanufacturing and Molecular diagnostics segments

Biomanufacturing

Focus on Cell & Gene Therapies

• Enzymes (Nucleases) utilized in the production process of gene therapy (viral vectors)
• FDA expects more 200 INDs/year and 10-20 approvals/year from 2025 within CGT

Molecular diagnostics / research

Enzymes for driving assay technologies and innovation

• New technologies and chemistry driving growth
• Increasing Compliance
• Infectious diseases prevalence increasing

Best-in-class Enzymes

Custom and OEM solutions – to meet customer's needs

Biomanufacturing (Therapeutics)

Viral vector, gene therapy and protein production

Removal of nucleic acids during protein production, vaccine manufacturing and viral vector preparation.

M-SAN HQ

Molecular Workflows

(Research & Molecular Diagnostics)

T7 Polymerase

5

Strategic priorities

From Strong Fundamentals to Sustained Growth

Customer Centric transformation

7

Evolving Commercial Processes and Culture

Q1 2025 – All time high in customer numbers

Early indication of customer centric transformation

Unique customers reached their highest level in recent years, driven by biomanufacturing growth

Biomanufacturing

• Orders increase, customer base continues to grow across NA and EMEA
• Increase in both opportunities made and customer pipeline stage progression

Molecular Tools

• Orders and customer base contracting, with stable AOV
• Lower demand from key Life Science and Diagnostic customers impacted sales

Biomanufacturing Q1

Molecular Tools Q1

Partnerships Biomanufacturing

CDMO opportunities

Becoming the standard nuclease on a CDMO platform

• Trend in the CGT space a return to the CDMO model
• Trough partnerships with CDMOs we will expand our reach significantly into several projects/clients
• M-SAN and SAN has been tested in an initial studies with good data outcome at CDMOs
• M-SAN enhances
  • Downstream recovery
  • Reduces DNA contamination
  • Minimizes vector aggregation, leading to cleaner, higher-quality lentiviral vectors
• Two CDMOs staring Q2/3 to implement SAN on their platforms

-

-

-

Future portfolio - Diversification

12

RNA based therapeutics

Targeting a broader Advanced Therapies Market

• Enzymes are key in development, analytics and manufacturing process of mRNA
• AZT is now exploring new innovations in the field of RNA therapeutics through RCN funded collaboration project.
• First major innovation is a sequence specific RNA cleaving enzyme enabling controlled fragmentation of RNA
• First patent filed February 7, 2023 further filing ongoing to secure broader IPR and lead market
• Multiple applications are possible, currently testing use for improving analytic methods for mRNA
• In contact with numerous companies with ongoing testing at 7 sites

Due to its large size, mRNA needs to be fragmented prior to analysis e.g. using LC-MS. ET-N1 can speed up and simplify the cleaving process prior to analysis.

Outlook 2025

The market

• Opportunities plentiful in a dynamic macroeconomic environment
• Dialogues with Biomanufacturing customers are many and positive
• Still ground to cover SAN is still new to many

Customer centric transformation:

• Customer base is expanding new all time high
• Will continue to invest in organization and activities

CDMO platform partnerships:

• Platform implementation at two CDMOs
• Working on onboarding more

Product portfolio expansion:

• New GMP grade nuclease will be launched mid 2025
• RNA restriction enzyme ET-N1 has entered development phase

Confident in our ability to execute on our strategic priorities and create shareholder value

Thank you